{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Revance Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"RVNC"},"Address":{"label":"Address","value":"1222 DEMONBREUN STREET,SUITE 2000, NASHVILLE, Tennessee, 37203, United States"},"Phone":{"label":"Phone","value":"+1 615 724-7755"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products."},"CompanyUrl":{"label":"Company Url","value":"https://www.revance.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Azita Nejad","title":"Senior Vice President-Technical Operations"},{"name":"Conor Gallagher","title":"Head-Medical Affairs & Aesthetics"},{"name":"David A. Hollander","title":"Chief Medical Officer"},{"name":"Mark J. Foley","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}